Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vildagliptin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients
Eligibility Criteria
Inclusion Criteria:
- age: ≥ 70 years inclusive at Visit 1.
- patients with a confirmed diagnosis of T2DM
- HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled
- body mass index (BMI) in the range of 19-45kg/m2
Exclusion Criteria:
- FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)
- previous or current participation in any vildagliptin clinical study.
- history of hypersensitivity to DPP-4 inhibitors.
- concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
- donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vildagliptin
Placebo
Arm Description
Outcomes
Primary Outcome Measures
To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo
Secondary Outcome Measures
To evaluate the safety and tolerability of vildagliptin in elderly patients with T2DM who are drug-naive or inadequately controlled with oral antidiabetic drugs (OADs) including physical exam, vital sign, hematology, chemistry and electrocardiogram.
To evaluate the proportion of vildagliptin treated patients achieving fasting plasma glucose (FPG) reduction relative to placebo
To assess the responder rates of patients treated with vildagliptin as compared to placebo
Full Information
NCT ID
NCT01257451
First Posted
December 6, 2010
Last Updated
December 14, 2012
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT01257451
Brief Title
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Official Title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
431 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vildagliptin
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Intervention Description
vildagliptin 50mg bid
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 50mg bid
Primary Outcome Measure Information:
Title
To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
To evaluate the safety and tolerability of vildagliptin in elderly patients with T2DM who are drug-naive or inadequately controlled with oral antidiabetic drugs (OADs) including physical exam, vital sign, hematology, chemistry and electrocardiogram.
Time Frame
24 weeks
Title
To evaluate the proportion of vildagliptin treated patients achieving fasting plasma glucose (FPG) reduction relative to placebo
Time Frame
24 weeks
Title
To assess the responder rates of patients treated with vildagliptin as compared to placebo
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age: ≥ 70 years inclusive at Visit 1.
patients with a confirmed diagnosis of T2DM
HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled
body mass index (BMI) in the range of 19-45kg/m2
Exclusion Criteria:
FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)
previous or current participation in any vildagliptin clinical study.
history of hypersensitivity to DPP-4 inhibitors.
concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals Corporation
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Buizingen
ZIP/Postal Code
1501
Country
Belgium
Facility Name
Novartis Investigative Site
City
De Pinte
ZIP/Postal Code
9840
Country
Belgium
Facility Name
Novartis Investigative Site
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
Novartis Investigative Site
City
Mouscron
ZIP/Postal Code
7700
Country
Belgium
Facility Name
Novartis Investigative Site
City
Nazareth
ZIP/Postal Code
9810
Country
Belgium
Facility Name
Novartis Investigative Site
City
Oostham
ZIP/Postal Code
3945
Country
Belgium
Facility Name
Novartis Investigative Site
City
Wichelen
ZIP/Postal Code
9260
Country
Belgium
Facility Name
Novartis Investigative Site
City
Blagoevgrad
ZIP/Postal Code
2700
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Dimitrovgrad
ZIP/Postal Code
6400
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Plovdiv
ZIP/Postal Code
4001
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Varna
ZIP/Postal Code
9002
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Lahti
State/Province
Suomi
ZIP/Postal Code
15110
Country
Finland
Facility Name
Novartis Investigative Site
City
Helsinki
ZIP/Postal Code
00180
Country
Finland
Facility Name
Novartis Investigative Site
City
Oulu
ZIP/Postal Code
FIN-90100
Country
Finland
Facility Name
Novartis Investigative Site
City
Bamberg
ZIP/Postal Code
96050
Country
Germany
Facility Name
Novartis Investigative Site
City
Beckum
ZIP/Postal Code
59269
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
Novartis Investigative Site
City
Falkensee
ZIP/Postal Code
14612
Country
Germany
Facility Name
Novartis Investigative Site
City
Lichtenfels
ZIP/Postal Code
96215
Country
Germany
Facility Name
Novartis Investigative Site
City
Lutherstadt Eisleben
ZIP/Postal Code
06295
Country
Germany
Facility Name
Novartis Investigative Site
City
Magdeburg
ZIP/Postal Code
39112
Country
Germany
Facility Name
Novartis Investigative Site
City
Mammendorf
ZIP/Postal Code
82291
Country
Germany
Facility Name
Novartis Investigative Site
City
Münster
ZIP/Postal Code
48143
Country
Germany
Facility Name
Novartis Investigative Site
City
Potsdam
ZIP/Postal Code
14469
Country
Germany
Facility Name
Novartis Investigative Site
City
Sulzbach-Rosenberg
ZIP/Postal Code
92237
Country
Germany
Facility Name
Novartis Investigative Site
City
Völlkingen
ZIP/Postal Code
66333
Country
Germany
Facility Name
Novartis Investigative Site
City
Wetter
ZIP/Postal Code
58300
Country
Germany
Facility Name
Novartis Investigative Site
City
Bratislava
State/Province
Slovak Republic
ZIP/Postal Code
811 02
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Lubochna
State/Province
Slovak Republic
ZIP/Postal Code
03491
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
ZIP/Postal Code
040 22
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Levice
ZIP/Postal Code
934 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Nové Zámky
ZIP/Postal Code
940 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Pie¿¿any
ZIP/Postal Code
92101
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Ruzomberok
ZIP/Postal Code
034 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Sanlúcar de Barrameda
State/Province
Andalucía
ZIP/Postal Code
11540
Country
Spain
Facility Name
Novartis Investigative Site
City
Centelles
State/Province
Barcelona
ZIP/Postal Code
08540
Country
Spain
Facility Name
Novartis Investigative Site
City
Alzira
State/Province
Comunidad Valenciana
ZIP/Postal Code
46600
Country
Spain
Facility Name
Novartis Investigative Site
City
Alicante
ZIP/Postal Code
03114
Country
Spain
Facility Name
Novartis Investigative Site
City
Truro
State/Province
Cornwall
ZIP/Postal Code
TR1 3LJ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Exeter
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Stevenage
ZIP/Postal Code
SG1 4AB
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Wiltshire
ZIP/Postal Code
SN15 2SB
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
23706759
Citation
Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldanius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013 Aug 3;382(9890):409-416. doi: 10.1016/S0140-6736(13)60995-2. Epub 2013 May 23.
Results Reference
derived
Learn more about this trial
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
We'll reach out to this number within 24 hrs